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From 1976 to 1988, 63 patients received radiation therapy for primary cancers of 
the extrahepatic biliary system (eight gallbladder and 55 extrahepatic biliary duct). 
Twelve patients underwent orthotopic liver transplantation. Chemotherapy was 
administered to 13 patients. Three patients underwent intraluminal brachytherapy 
alone (range, 28 to 55 Gy). Sixty patients received megavoltage external-beam 
radiation therapy (range, 5.4 to 61.6 Gy; median, 45 Gy), of whom nine received 
additional intraluminal brachytherapy (range, 14 to 45 Gy; median, 30 Gy). The 
median survival of all patients was 7 months. Sixty patients died, all within 39 
months of radiation therapy. One patient is alive 11 months after irradiation 
without surgical resection, and two are alive 50 months after liver transplantation 
and irradiation. Symptomatic duodenal ulcers developed after radiation therapy in 
seven patients but were not significantly related to any clinical variable tested. 
Extrahepatic biliary duct cancers, the absence of metastases, increasing calendar 
year of treatment, and liver transplantation with postoperative radiation therapy 
were factors significantly associated with improved survival. 
Cancer 68:289-294,1991. 
C ARCINOMAS arising in the gallbladder or extrahepatic biliary ducts are uncommon and generally have a 
poor prognosis; the overall 5-year survival is less than 
10%.1-9 Death is usually from locoregional disease rather 
than distant metastases. 10,1 I Direct invasion into adjacent 
structures and metastases to regional lymph nodes, par-
ticularly in the porta hepatis are the main routes of spread. 
The liver is involved in 40% to 50% of case8,10 and ret-
roperitoneallymph nodes in 20% of patients.8,lo,12 Peri-
toneal spread occurs in 9% of extrahepatic biliary duct 
cancers and 20% of gallbladder cancers.8,12 Direct exten-
sion of disease into the liver or liver metastases occurs 
commonly, even with small tumors. 1O,13 Cholangiocar-
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cinomas have a tendency to spread along the biliary tract 
and are multifocal in as many as 42% of patients. 14 
Complete surgical resection is often impossible because 
oftumor spread. Approximately 30% of cases are resect-
able, but this varies between 5% and 61 %, depending on 
patient selection. I ,2,5,9,15-2o The diagnosis of cholangio-
carcinoma at the bifurcation of the common duct (Klat-
skin tumor) is sometimes difficult to make preoperatively; 
computed tomographic or magnetic resonance scans may 
not show the tumor, and there are difficulties in estab-
lishing a cytologic diagnosis from needle biopsies or 
brushings. Therefore, some patients undergoing liver 
transplantation for end-stage liver disease, such as scle-
rosing cholangitis, are found to have a cholangiocarci-
noma that is undetected until liver transplantation is done, 
and the recipient liver is examined. The initial results re-
ported for liver transplantation of cholangiocarcinoma 
have been discouraging, primarily because oflocal tumor 
recurrence. 1,21 
Radiation therapy has been used as primary treatment 
for unresectable cholangiocarcinomas, usually after per-
cutaneous transhepatic biliary drainage has been estab-
lished for relief of jaundice. 4,6,10, 11,13,16,22-36 It has also been 
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used as adjuvant therapy after resection. Radiation ther-
apy has been delivered with fractionated external-beam 
treatment, intracavitary irradiation, or a combination of 
the two. Intraoperative radiation therapy has also been 
used with some success.37 We review our recent experience 
with radiation treatment of these tumors at a major ter-
tiary-care referral cen.ter for liver surgery. 
Materials and Methods 
Between 1976 to 1988, 63 patients were referred to the 
Joint Radiation Oncology Center at the University of 
Pittsburgh Medical Center for radiation of primary ma-
lignant tumors of the gallbladder or extrahepatic biliary 
ducts. Twenty-six of these patients were reported earlier. II 
A pathologic diagnosis of adenocarcinoma was established 
before radiation therapy in 54 patients. In the remaining 
nine patients, the radiographic diagnosis of Klatskin tu-
mor was made by percutaneous transhepatic cholangio-
gram and/or endoscopic retrograde cholangiopancrea-
tography. Eight patients had unresectable primary or re-
current carcinoma of the gallbladder with involvement of 
the liver. The other 55 patients had tumors involving the 
proximal hepatic ducts. Additional clinical characteristics 
are listed in Table 1. 
Three patients underwent gross total resection of tumor 
without liver transplantation. Twelve patients underwent 
orthotopic liver transplantation. Eight were referred for 
postoperative radiation therapy, one for preoperative ir-
radiation, and three for radiation therapy after tumor re-
currence. To simplify the data analysis, the patient with 
preoperative radiation therapy was included with the liver 
. transplant plus postoperative radiation therapy group. 
Twenty-two patients were referred for radiation after par-
tial tumor resection. Twenty-six patients were referred for 
radiation therapy with no surgical resection attempted. 
TABLE 1. Clinical Characteristics 
Characteristic No. 
Age 
< 60 yr 32 
2: 60 yr 31 
Sex 
Male 32 
Female 31 
Prior liver disease 14 
No prior liver disease 49 
Gallbladder primary 8 
Extrahepatic biliary duct 55 
Systemic metastases 10 
No systemic metastases 53 
Lymphadenopathy 10 
No lymphadenopathy 29 
Nodes not assessed 24 
Percent 
51 
49 
51 
49 
22 
88 
13 
87 
16 
84 
16 
46 
38 
Chemotherapy consisting of 5 fluorouracil (5-FU) or a 
combination of 5-FU, doxorubicin, and mitomycin C 
(F AM) was administered to 13 patients. 
Total radiation doses administered ranged from 5.40 
to 82.37 Gy (median, 47.5 Gy). Three patients received 
intraluminal brachytherapy alone (28.0, 29.6, and 55.0 
Gy at 0.5-cm depth). Sixty patients received megavoltage 
external-beam irradiation to target absorbed doses of 5.40 
to 61.53 Gy (median, 45 Gy). Nine patients received boost 
intraluminal brachytherapy (range, 14 to 45 Gy to 0.5-
cm depth; median, 30 Gy) combined with 26 to 60 Gy 
(median, 47.6 Gy) of external-beam irradiation. Nor-
malized total doses at 2 Gy per fraction (NTD2) were 
calculated using linear quadratic factor parameters for 
small bowel tolerance. 38- 41 The NTD2 values for external-
beam irradiation ranged from 5.83 to 61.56 Gy (median, 
45.7 Gy). Two fields were irradiated in ten patients, three 
in 20 patients, and four in 30 patients. Field sizes ranged 
from 36 to 702 cm2 (median, 100 cm2). Eight patients 
were treated with cobalt 60, and 52 patients were irradiated 
with a 6-MV, 8-MV, or 18-MV photon beam. Fifteen 
patients were treated with planned split-course irradiation 
beginning with 25 Gy in ten fractions followed by a 3 to 
4-week break.42 Patients with stable medical conditions 
received another 25 Gy in ten fractions for a total dose 
of 50 Gy. 
Actuarial survival from the start of radiation therapy 
was calculated using the method of Kaplan and Meier. 43 
Actuarial ulcer-free survival was calculated in a similar 
manner with the development of symptomatic ulcers as 
the end point and patient deaths considered as censored 
outcomes. The effects of different clinical or treatment 
parameters on both survival and development of symp-
tomatic ulcers were examined with univariate analysis us-
ing the log-rank test.44 
Results 
Overall survival is illustrated in Figure 1. Sixty patients 
died 1 to 39 months after starting radiation therapy. Three 
patients are alive without evidence of disease at 11, 50, 
and 50 months after therapy (median survival, 7 months). 
The cause of death was judged to be cancer in all cases 
except one patient who received preoperative irradiation 
of 22.5 Gy for a biopsy-proven Klatskin tumor. This pa-
tient underwent an orthotopic liver transplant and died 
within 1 month of surgery from transplant rejection. No 
evidence of residual cholangiocarcinoma was found in 
the resected liver. The only two long-term survivors un-
derwent orthotopic liver transplantation and are now dis-
ease-free 50 months after postoperative irradiation. 
Among the nine patients who received postoperative ra-
diation therapy after liver transplantation, the actuarial 
survival was 22% at both 2 and 4 years. 
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FIG. 1. Actuarial survival of all patients receiving radiation therap) 
for cholangiocarcinoma (n = 63). Numbers in parentheses indicate the 
number of patients at risk. 
Table 2 lists the results of univariate testing of overall 
survival for 16 clinical parameters using the log-rank test. 
Neither the total radiation dose nor the external beam 
NTD2 value administered represented true pretreatment 
variables because, if a patient's clinical condition deteri-
orated, his course of radiation was stopped (particularly 
with the split-course technique), and/or brachytherapy was 
withheld. To eliminate the bias of this effect on the total 
radiation dose administered, the analysis was repeated 
excluding the 13 patients who died within 2 months of 
TABLE 2. Univariate Survival Analyses for All 63 Patients and 
for 50 Patients Surviving More Than 2 Months 
Factor 
Ex trahepatic biliary duct 
. Year of treatment 
Transplant and postoperative radiotherapy 
Total radiation dose 
Surgery, extent 
NTD2.t external beam 
Sex 
Systemic metastases 
Prior liver disease 
Initial tissue diagnosis 
Age 
Brachytherapy 
Chemotherapy 
Split-course irradiation 
Field size 
Lymphadenopathy 
• Statistical significance (P < 0.05). 
t Normalized total dose at 2 Gy per fraction. 
Pvalue P value 
(n = 63) (n = 50) 
0.0005* 0.0001* 
0.0221* 0.0229* 
0.0313" 0.0413" 
0.0394' 0.9882 
0.0430' 0.0721 
0.0488* 0.3659 
0.0714 0.0970 
0.1136 0.0520 
0.1404 0.1856 
0.3531 0.1611 
0.3937 0.8909 
0.4340 0.8670 
0.4454 0.1143 
0.5936 0.5262 
0.6502 0.6344 
0.9376 0.4889 
starting irradiation. As shown in Table 2, univariate anal-
ysis of the entire group of 63 patients demonstrated sig-
nificantly improved survival with liver transplantation and 
postoperative radiation therapy (P = 0.031), increasing 
extent of surgical resection (P = 0.043), increasing total 
dose (P = 0.039), increasing external beam NTD2 value 
(P = 0.048), increasing calendar year of radiation treat-
ment (P = 0.022), and extrahepatic duct tumors compared 
with gallbladder primaries (P = 0.005). When the analysis 
was repeated excluding those patients living 2 months or 
less after initiating radiation therapy (to remove dose-se-
lection bias), neither total radiation dose nor external 
beam NTDz value were significantly associated with im-
proved survival (P = 0.98 and 0.37, respectively). Extra-
hepatic duct primaries (P < 0.0001), increasing calendar 
year of treatment (P = 0.023), and liver transplantation 
with postoperative radiation therapy (P = 0.041) were all 
significantly associated with increased survival. Patients 
with systemic metastases had a decrease in survival that 
approached statistical significance (P = 0.052). 
The actuarial survival curves for patients with gall-
bladder primaries (median survival, 3 months) and those 
with extrahepatic biliary duct primaries (median survival, 
9 months) are shown in Figure 2. The actuarial survival 
curve for patients who underwent liver transplantation 
and postoperative radiation therapy (n = 9) was compared 
with the survival curve for the other patients in the series 
(n = 54) in Figure 3. 
Seven patients had symptomatic duodenal ulcers 3, 4, 
6,8,8,9, and 17 months after radiation. One patient who 
received split-course radiation therapy to a target absorbed 
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FIG. 2. Actuarial survival of patients with gallbladder primaries (n 
= 8) compared with patients with extrahepatic biliary duct primaries (n 
= 55). Numbers in parentheses indicate the number of patients at risk. 
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FIG. 3. Actuarial survival of patients undergoing liver transplantation 
with preoperative or postoperative radiation therapy (n = 9) compared 
with patients receiving more conservative therapy (n = 54). Numbers in 
parentheses indicate the number of patients at risk. 
dose of 50 Gy in 20 fractions had a duodenal stricture 
requiring dilatation. Ulcers in the other six patients were 
managed successfully with medical therapy. Table 3 shows 
the results of univariate analysis of ulcer-free survival for 
11 different clinical or treatment factors; none was statis-
tically associated with ulcer development. The actuarial 
risk of developing a symptomatic duodenal ulcer at 2 years 
was 29% (Fig. 4). 
Discussion 
Primary carcinomas of the extrahepatic biliary passages 
are aggressive tumors with a poor prognosis. We could 
not demonstrate significant survival benefits for surgical 
resection short ofliver transplantation, chemotherapy, or 
high doses of external-beam radiation therapy plus intra-
luminal brachytherapy. Liver transplantation with post-
operative radiation therapy appears to be the only treat-
ment factor studied that improved survival of our 
TABLE 3. Ulcer-Free Survival Analysis 
Factor P value (n = 50) 
Split-course irradiation 
Number of fields 
Surgery, extent 
Total dose 
Brachytherapy 
NTD2, t external beam 
Prior liver disease 
Chemotherapy 
Liver transplant 
t Normalized total dose at 2 Gy per fraction. 
0.1377 
0.2535 
0.3334 
004045 
004201 
0.5331 
0.6438 
0.6264 
0.8402 
cholangiocarcinoma patients. This study did, however, 
identify two other factors that were of prognostic value. 
The first factor was primary tumor location. The survival 
of patients with tumors originating in the gallbladder was 
inferior to that of patients with tumors originating in the 
extrahepatic bile ducts. Because the only patients with 
primary gallbladder tumors referred for radiation therapy 
had unresectable tumors with liver invasion, our patients 
with gallbladder tumors were highly selected. This selec-
tion factor explains the low proportion of gallbladder tu-
mors (13%) compared with other series (average, 60%).34 
The second prognostic factor associated with improved 
survival was increasing calendar year of radiation treat-
ment. This may be the result of improvements in sup-
portive care for patients treated later. 
The optimum treatment approach to cholangiocarci-
nomas is unclear. Biliary decompression alone appears to 
improve the mean survival of patients with Klatskin tu-
mors from 3 months with no treatment to about 9 
months. 15,31,46 In separate reports, others found mean 
survival rates of 12 to 18 months with fractionated ex-
ternal-beam irradiation. 16,18 Using intraluminal brachy-
therapy alone, Fletcher et aI. 6,26,31 showed a median sur-
vival of 11 months which improved to 17 months in a 
later update. Several other authors reported on the use of 
external-beam radiation therapy and brachytherapy for 
cholangiocarcinoma,z4,25,30,34,36 Johnson et aUo reported 
median survivals of 9 months after implantation alone 
and 16 months after external-beam irradiation with and 
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FIG. 4. Actuarial survival for freedom from symptomatic duodenal 
ulcers (n = 63). Numbers in parentheses indicate the number of patients 
at risk. 
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intraluminal brachytherapy (seven patients). Others found 
a median survival of 7 months in nine patients receiving 
external-beam radiation therapy alone compared with 15 
months in eight patients who received combined brachy-
therapy and external-beam irradiation25 and average sur-
vivals of3.6 months in five patients receiving intraluminal 
brachytherapy alone compared with 14 months with ex-
ternal-beam irradiation and intraluminal brachytherapy.34 
Selection factors may affect the choice of therapy and 
lead to survival differences. This appears to be the case 
in our series. Our initial analysis of the entire group of 63 
patients showed that high total radiation dose (which is 
greatest in the combined brachytherapy and external-
beam group) was associated significantly with improved 
survival. This improvement could not be substantiated, 
however, when a repeat analysis to eliminate dose-selec-
tion bias was limited to those patients surviving more 
than 2 months after the start of radiation therapy. Thus, 
the reason higher doses of radiation appeared to improve 
survival in our original analysis seems to be that patients 
who would have been treated with high-dose radiation 
therapy but did not live long enough to complete the 
treatment were analyzed subsequently in the low-dose 
group. 
The development of symptomatic duodenal ulcers was 
not statistically significant with either radiation dose or 
field size, suggesting that other factors such as biliary 
drainage catheters or surgical biliary diversion contributed 
to their development. Nevertheless, this lack of association 
should not be overinterpreted because our analysis was 
limited by short survival times. Prophylactic treatment to 
prevent peptic ulcers may be indicated in some patients 
undergoing radiation therapy for cholangiocarcinoma. 
Partial or complete surgical hepatic resection, short of 
liver transplantation, was not associated with improved 
survivaL Most surgical series report median survival of 
20 months with gross total resection compared with 9 
months for palliative surgical procedures. 2.5.9.12,15-17,20,45,46 
The selection of patients with smaller tumors for curative 
resection may account for the better survival of patients 
undergoing complete resections. Our series did not contain 
enough patients who underwent complete resection with-
out liver transplantation to analyze this group separately. 
Although the extent of surgical resection was prognosti-
cally important in the initial analysis (P = 0.043), this did 
not remain significant in the repeat analysis (P = 0.072) 
despite the fact that liver transplant patients included most 
of the patients in the complete resection group. We did 
find that patients who underwent liver transplantation 
with postoperative radiation therapy had a modest but 
significant improvement in survival (P = 0.031). Because 
of the small number of patients in this study and the large 
number of clinical variables tested, a valid multivariate 
analysis could not be done to test for the effects of possible 
confounding variables (such as primary site or year of 
treatment) on the better outcome observed with liver 
transplantation and radiation therapy. That the only two 
long-term (50-month) survivors in this series underwent 
liver transplantation with postoperative radiation therapy, 
however, provides clear encouragement for additional in-
vestigation of liver transplantation for cholangiocarci-
noma. 
Partial response rates of 29% have been reported for 
systemic chemotherapy with drugs such as 5-FU and mi-
tomycin C as single agents or in combinations, such as 
FAM.47 Our initial experience with chemotherapy in these 
tumors was disappointing. On the other hand, Minsky et 
at. 13 reported an encouraging preliminary experience using 
chemotherapy combined with aggressive radiation ther-
apy. Although they reported five of ten patients alive 
without disease 16, 17, 17, 48, and 52 months after com-
bined treatment, the two longest survivors had no tissue 
diagnosis. We found an insignificant trend toward better 
survival (P = 0.16) in patients without an initial tissue 
diagnosis, possibly because of smaller tumor size. None-
theless, tumor progression eventually confirmed the di-
agnosis of cholangiocarcinoma in all such patients in our 
senes. 
In conclusion, we showed a modest but significant im-
provement in survival using liver transplantation and 
postoperative radiation therapy but no significant im-
provement using radiation therapy even with higher doses 
of radiation, conventional surgical resection, or chemo-
therapy. Except for patients with small tumors that can 
be completely resected, the prognosis for patients with 
cholangiocarcinoma is poor with conventional therapy. 
More radical treatment strategies, such as upper abdom-
inal exenteration with cluster organ transplantation or 
liver transplantation with intensive preoperative radiation 
therapy and/or chemotherapy, may offer a better chance 
for cure in patients with unresectable cholangiocarcinoma. 
These strategies are currently being investigated at the 
University of Pittsburgh Medical Center. 
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